The Statin Replacement We’ve Been Waiting For!

1 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
A new cholesterol-lowering drug is being called a “breakthrough,” a “bazooka,” and even a lifesaving discovery — but does the data actually support the headlines? In this video, we take a clear, balanced look at PCSK9 inhibitors, the latest class of LDL-lowering monoclonal antibody drugs that claim to outperform statins. A recent New England Journal of Medicine trial reports a 25% relative reduction in cardiovascular events, but the real impact becomes far more nuanced when you look at the absolute risk reduction, the high-risk population studied, and the size of the trial needed to detect the effect. We walk through primary vs secondary prevention, the difference between risk framing, and why some trials look more impressive on paper than they are in real-world outcomes.

You’ll also learn how PCSK9 inhibitors work biologically, why monoclonal antibodies aren’t the same as traditional drugs, and how lowering LDL fits into the old cholesterol model vs the emerging metabolic-syndrome model of heart disease. We explore triglycerides, HDL, ApoB, inflammation, and why lifestyle changes — especially low-carb approaches — have never been included as comparison arms in these large drug trials. We also look at the downsides of statins, insulin resistance concerns, and why many people report better improvements through diet than medication alone. This video breaks down what the trial actually proves, what it doesn’t, and what still remains unanswered in the cholesterol debate.

pcsk9 inhibitors explained, evolocumab NEJM trial, new cholesterol drug review, LDL lowering drugs, statins vs pcsk9, absolute vs relative risk, heart disease prevention science, metabolic syndrome approach, triglycerides and HDL, cholesterol debate explained, monoclonal antibody drugs, cardiovascular trial analysis, lipid lowering medication risks, cholesterol lowering controversy, low carb vs statins, lifestyle vs medication heart disease, cardiology breakthrough claims, LDL vs ApoB explained, insulin resistance and statins, heart attack and stroke prevention

Categoria
Cardiology
Tags
keto, lowcarb, highfat
Commenta per primo questo video.

Prossimo